IBRX
Price
$3.68
Change
-$0.30 (-7.54%)
Updated
Nov 30, 6:59 PM EST
88 days until earnings call
MDGL
Price
$203.30
Change
+$5.94 (+3.01%)
Updated
Nov 30, 6:59 PM EST
83 days until earnings call
Ad is loading...

Analysis and predictions IBRX vs MDGL

Header iconIBRX vs MDGL Comparison
Open Charts IBRX vs MDGLBanner chart's image
ImmunityBio
Price$3.68
Change-$0.30 (-7.54%)
Volume$3M
CapitalizationN/A
Madrigal Pharmaceuticals
Price$203.30
Change+$5.94 (+3.01%)
Volume$153.12K
CapitalizationN/A
View a ticker or compare two or three
IBRX vs MDGL Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
IBRX vs. MDGL commentary
Dec 01, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IBRX is a StrongSell and MDGL is a Buy.

COMPARISON
Comparison
Dec 01, 2023
Stock price -- (IBRX: $3.68 vs. MDGL: $203.30)
Brand notoriety: IBRX and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IBRX: 50% vs. MDGL: 34%
Market capitalization -- IBRX: $2.82B vs. MDGL: $3.9B
IBRX [@Biotechnology] is valued at $2.82B. MDGL’s [@Biotechnology] market capitalization is $3.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IBRX’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 0 green FA rating(s).

  • IBRX’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 0 green, 5 red.
According to our system of comparison, both IBRX and MDGL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IBRX’s TA Score shows that 5 TA indicator(s) are bullish while MDGL’s TA Score has 6 bullish TA indicator(s).

  • IBRX’s TA Score: 5 bullish, 6 bearish.
  • MDGL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than IBRX.

Price Growth

IBRX (@Biotechnology) experienced а -12.17% price change this week, while MDGL (@Biotechnology) price change was +6.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.35%. For the same industry, the average monthly price growth was +26.89%, and the average quarterly price growth was +20.28%.

Reported Earning Dates

IBRX is expected to report earnings on Feb 27, 2024.

MDGL is expected to report earnings on Feb 22, 2024.

Industries' Descriptions

@Biotechnology (+2.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for IBRX with price predictions.
OPEN
A.I.dvisor published
a Summary for MDGL with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MDGL($3.9B) has a higher market cap than IBRX($2.82B). IBRX YTD gains are higher at: -27.416 vs. MDGL (-29.957). IBRX has higher annual earnings (EBITDA): -313.92M vs. MDGL (-336.4M). MDGL has more cash in the bank: 232M vs. IBRX (190M). MDGL has less debt than IBRX: MDGL (117M) vs IBRX (717M). IBRX has higher revenues than MDGL: IBRX (556K) vs MDGL (0).
IBRXMDGLIBRX / MDGL
Capitalization2.82B3.9B72%
EBITDA-313.92M-336.4M93%
Gain YTD-27.416-29.95792%
P/E RatioN/AN/A-
Revenue556K0-
Total Cash190M232M82%
Total Debt717M117M613%
FUNDAMENTALS RATINGS
IBRX vs MDGL: Fundamental Ratings
IBRX
MDGL
OUTLOOK RATING
1..100
9549
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
94100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3535
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBRX's Valuation (90) in the Biotechnology industry is in the same range as MDGL (96) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew similarly to MDGL’s over the last 12 months.

IBRX's Profit vs Risk Rating (94) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew similarly to MDGL’s over the last 12 months.

IBRX's SMR Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew similarly to MDGL’s over the last 12 months.

IBRX's Price Growth Rating (35) in the Biotechnology industry is in the same range as MDGL (35) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew similarly to MDGL’s over the last 12 months.

IBRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that IBRX’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IBRXMDGL
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 16 days ago
87%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 22 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TYG28.130.22
+0.79%
Tortoise Energy Infrastructure Corp
SDVY29.430.16
+0.55%
First Trust SMID Cp Rising Div Achv ETF
HYGI25.52N/A
N/A
iShares Inflation Hedged Hgh Yld Bd ETF
OAEM28.36-0.16
-0.58%
OneAscent Emerging Markets ETF
SBI7.48-0.08
-1.06%
Western Asset Intermediate Muni Fund